In the last trading session, 1.16 million shares of the iBio Inc (NASDAQ:IBIO) were traded, and its beta was 0.60. Most recently the company’s share price was $0.84, and it changed around $0.06 or 6.51% from the last close, which brings the market valuation of the company to $13.56M. IBIO currently trades at a discount to its 52-week high of $6.89, offering almost -720.24% off that amount. The share price’s 52-week low was $0.64, which indicates that the current value has risen by an impressive 23.81% since then. We note from iBio Inc’s average daily trading volume that its 10-day average is 8.8 million shares, with the 3-month average coming to 2.71 million.
iBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended IBIO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. iBio Inc is expected to report earnings per share of -0.34 for the current quarter.
iBio Inc (NASDAQ:IBIO) trade information
Instantly IBIO has showed a green trend with a performance of 6.51% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.8668 on recent trading dayincreased the stock’s daily price by 3.09%. The company’s shares are currently down -57.58% year-to-date, but still up 9.51% over the last five days. On the other hand, iBio Inc (NASDAQ:IBIO) is -9.80% down in the 30-day period. We can see from the shorts that 0.83 million shares have been sold at a short interest cover period of 1.75 day(s).
The consensus price target as assigned by Wall Street analysts is $3.6, which translates to bulls needing to increase their stock price by 76.67% from its current value. Analyst projections state that IBIO is forecast to be at a low of $3.6 and a high of $3.6.
iBio Inc (IBIO) estimates and forecasts
The year-over-year growth rate is expected to be 48.15%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 66.67k in revenue for the current quarter. Analysts predict that the company’s current quarter sales will drop, forecast at -61.90%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 57.55%.
IBIO Dividends
iBio Inc’s next quarterly earnings report is expected to be released on 2025-May-02.
iBio Inc (NASDAQ:IBIO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.31% of iBio Inc shares, and 15.78% of them are in the hands of institutional investors. The stock currently has a share float of 16.49%. iBio Inc stock is held by 38.0 institutions, with LYNX1 CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 6.9576% of the shares, which is about 0.6 million shares worth $1.27 billion.
IKARIAN CAPITAL, LLC, with 6.9576% or 0.6 million shares worth $1.27 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 138.4 shares worth $0.12 million, making up 0.85% of all outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held roughly 54.08 shares worth around $45196.0, which represents about 0.33% of the total shares outstanding.
